Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells.
Bisphosphonates (BPs) are widely used in the treatment of osteolytic bone disease associated with multiple myeloma, and have been demonstrated to exert antitumor effects both in vitro and in vivo. However, the precise molecular mechanisms involved in the direct antitumor effects of BPs in vitro are...
Main Authors: | Roelofs, A, Hulley, P, Meijer, A, Ebetino, F, Russell, R, Shipman, C |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2006
|
Similar Items
-
Risedronate, and its phosphonocarboxylate analogue NE10790, both induce apoptosis, but have differential effects on the cell cycle and protein prenylation in human myeloma cells.
by: Roelofs, A, et al.
Published: (2004) -
NE10790, a phosphonocarboxylate analogue of risedronate, induces human myeloma cell apoptosis in vitro
by: Roelofs, A, et al.
Published: (2004) -
Studies to elucidate the anti-tumor mechanism of action of risedronate in human myeloma cells; Use of an analogue of risedronate reveals the effects of differential inhibition of prenylation
by: Roelofs, A, et al.
Published: (2005) -
Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate.
by: Marma, MS, et al.
Published: (2007) -
Apomine, an inhibitor of HMG-COA-reductase, does not act by inhibiting protein prenylation in human myeloma cells in vitro
by: Roelofs, A, et al.
Published: (2005)